Today [August 13] the US National Academy of Sciences is hosting the first meeting of the International Commission on the Clinical Use of Human Germline Genome Editing in Washington, to discuss controversial applications of CRISPR to human eggs, sperm, or fertilized ova, in the wake of Chinese researcher He Jiankui announcing the birth of CRISPR twins after a similar meeting in 2017 (See Do China's controversial CRISPR babies illustrate the need for an undo button?).
Although only one clinical trial is up-and-running for CRISPR to treat body cells, with an initial patient making the media rounds just last week to discuss her cells doctored to counter sickle cell disease, many other applications are in preclinical testing — animal models and human cells and organoids. And they're not restricted to rare diseases.
Imagine a single injection that quells the inflammation behind lower back pain — perhaps forever. CRISPR may make that possible by dampening the immune system's cytokine signals, according to a report in the July issue of Human Gene Therapy.
To continue reading, go to Genetic Literacy Project, where this post first appeared.